Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Schito, Marco ^a   Peter, Trevor F ^b   Cavanaugh, Sean ^c   Piatek, Amy S ^d   Young, Gloria J ^e   Alexander, Heather ^f   Coggin, William ^g   Domingo, Gonzalo J ^h   Ellenberger, Dennis ^f   Ermantraut, Eugen ⁱ   Jani, Ilesh V ^j   Katamba, Achilles ^k   Palamountain, Kara M ^l   Essajee, Shaffiq ^m   Dowdy, David W ⁿ  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^e BD Technologies   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g U S DEPARTMENT OF STATE   (United States)

^h PATH   (United States)

ⁱ Alere Technologies GmbH   (Germany)

^j INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^k MAKERERE UNIVERSITY   (Uganda)

^l NORTHWESTERN UNIVERSITY   (United States)

^m WORLD HEALTH ORGANIZATION   (Switzerland)

ⁿ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN;

ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LABORATORY TEST; MICROSCOPY; MICROTECHNOLOGY; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

BACTERIOLOGICAL TECHNIQUES; HIV INFECTIONS; HUMANS; LABORATORIES; POINT-OF-CARE SYSTEMS; QUALITY ASSURANCE, HEALTH CARE; TUBERCULOSIS; VIROLOGY;

EID: 84860373242     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis044     Document Type: Article

References (67)

1. Peeling RW, Mabey D. Point-of-care tests for diagnosing infections in the developing world. Clin Microbiol Infect 2010; 16:1062-9.
2. Crucitti T, Taylor D, Beelaert G, Fransen K, Van Damme L. Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol 2011; 18:1480-5.
3. Reynolds SJ, Muwonga J. OraQuick ADVANCE Rapid HIV-1/2 antibody test. Expert Rev Mol Diagn 2004; 4:587-91.
4. Centers for Disease Control and Prevention. False-positive oral fluid rapid HIV testsdNew York City, 2005-2008. MMWR Morb Mortal Wkly Rep 2008; 57:660-5.
5. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-68.
6. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-29.
7. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553-63.
8. Gras L, van Sighem A, Bezemer D, Smit C, Wit F, de Wolf F. Lower mortality and earlier start of combination antiretroviral therapy in patients tested repeatedly for HIV than in those with a positive first test. AIDS 2011; 25:813-8.
9. Cohen MS, Chen YQ,McCauleyM, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
10. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-93.
11. Pilcher CD, Eaton L, Kalichman S, Bisol C, de Souza Rda S. Approaching "HIV elimination": interventions for acute HIV infection. Curr HIV/AIDS Rep 2006; 3:160-8.
12. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med 2011; 9:59.
13. Creek TL, Sherman GG, Nkengasong J, et al. Infant human immunodeficiency virus diagnosis in resource-limited settings: issues, technologies, and country experiences. Am J Obstet Gynecol 2007; 197:S64-71.
14. Chohan BH, Emery S, Wamalwa D, et al. Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting. BMC Pediatr 2011; 11:18.
15. Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G. Vaccine-induced HIV seropositivity: a problem on the rise. J Clin Virol 2011; 50:334-7.
16. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR. Vaccineinduced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 2010; 304:275-83.
17. Schito ML, D'Souza MP, Owen SM, Busch MP. Challenges for rapid molecular HIV diagnostics. J Infect Dis 2010; 201(Suppl 1):S1-6.
18. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab 2007; 53:135-48.
19. Corbett EL, Zezai A, Cheung YB, et al. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ 2010; 88:13-21.
20. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data metaanalysis of observational studies. PLoS Med 2011; 8:e1000391.
21. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-9.
22. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675-85.
23. Wilson D, Nachega J, Morroni C, Chaisson R, Maartens G. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int J Tuberc Lung Dis 2006; 10:31-8.
24. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
25. Creswell J, Falzon D, Getahun H, et al. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "how-to"; practical considerations. Vol 2011. Geneva, Switzerland: WHO, 2011.
26. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
27. Smith S, Kurbatova E, Cavanaugh J, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2011; 16:203-5.
28. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241501545-eng.pdf. Accessed 26 October 2011.
29. Usdin M, Guillerm M, Calmy A. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. J Infect Dis 2010; 201(Suppl 1):S73-7.
30. Batz HG, Cooke GS, Reid SD. Towards lab-free tuberculosis diagnosis. Treatment Action Group; Stop TB Partnership, Imperial College London and the MSF Access Campaign, London, UK, 2011.
31. Girosi F, Olmsted SS, Keeler E, et al. Developing and interpreting models to improve diagnostics in developing countries. Nature 2006; 444(Suppl 1):3-8.
32. National Coordinating Agency for Population and Development (NCAPD) Mo Medical Services (MoMS) MoPHaSMK, Kenya National Bureau of Statistics (KNBS). IMKSP, Assessment Survey 2010. Nairobi KNCAfPa, Development MoMS, Ministry of Public Health and Sanitation, Kenya and National Bureau of Statistics aIM. Kenya Service Provision Assessment Survey 2011, 2011. www.ncapd-ke.org/index. php?option=com-docman&Itemid=181. Accessed 5 February 2012.
33. Ministry of Health (MOH) [Uganda] and Macro International Inc. 2008. Uganda Service Provision Assessment Survey 2007. Kampala, Uganda: Ministry of Health and Macro International Inc.
34. Thairu L, Katzenstein D, Israelski D. Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa. AIDS Care 2011; 23:814-21.
35. Jani IV, Sitoe NE, Chongo PL, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 2011; 25:807-12.
36. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr 2010; 55:1-7.
37. Mahy M, Stover J, Kiragu K, et al. What will it take to achieve virtual elimination of mother-to-child transmission of HIV? An assessment of current progress and future needs. Sex Transm Infect 2010; 86(Suppl 2): ii48-55.
38. Birx D, de Souza M, Nkengasong JN. Laboratory challenges in the scaling up of HIV, TB, and malaria programs: the interaction of health and laboratory systems, clinical research, and service delivery. Am J Clin Pathol 2009; 131:849-51.
39. Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378:1572-9.
40. Consultation on Technical and Operational Recommendations for Clinical Laboratory Testing Harmonization and Standardization. Helping to expand sustainable quality testing to improve the care and treatment of people infected with and affected by HIV/AIDS, TB and malaria. Maputo, Mozambique, 2008. www.who.int/hiv/amds/amds-cons-tech-oper
41. Peter TF, Rotz PD, Blair DH, Khine AA, Freeman RR, Murtagh MM. Impact of laboratory accreditation on patient care and the health system. Am J Clin Pathol 2010; 134:550-5.
42. Nkengasong JN. A shifting paradigm in strengthening laboratory health systems for global health: acting now, acting collectively, but acting differently. Am J Clin Pathol 2010; 134:359-60.
43. Nakyanzi JK, Kitutu FE, Oria H, Kamba PF. Expiry of medicines in supply outlets in Uganda. Bull World Health Organ 2010; 88:154-8.
44. World Health Organization. Task shifting: global recommendations and guidelines. Geneva, Switzerland: WHO, 2008. www.who.int/healthsystems/TTR- TaskShifting.pdf. Accessed 27 October 2011.
45. World Health Organization, US Department of Health and Human Services CfDCaP. Guidelines for assuring the accuracy and reliability of HIV rapid testing: applying a quality system approach. Geneva, Switzerland: WHO, 2005. www.who.int/entity/diagnostics
46. WorldHealth Organization. Field safety notice no. 1. Geneva, Switzerland: WHO, 2011. http://www.who.int/diagnostics
47. World Health Organization. Update information on the SD Bioline HIV-1/2 v3.0. Geneva, Switzerland: WHO, 2011. http://www.who.int/diagnostics
48. US Agency for International Development. List of approved HIV/AIDS rapid test kits. 2011. http://www.usaid.gov/our-work/global-health/aids/TechAreas/ treatment/hiv-tests.pdf. Accessed 5 January 2012.
49. AIDS Institute and Wadsworth Center, New York State Department of Health. Rapid HIV testing workbook and implementation guidelines for limited testing sites in New York State. Albany, NY: New York State Department of Health, 2005. www.health.state.ny.us/diseases/aids/testing/rapid/docs/workbook.pdf. Accessed 27 October 2011.
50. Yao K, Wafula W, Bile EC, et al. Ensuring the quality of HIV rapid testing in resource-poor countries using a systematic approach to training. Am J Clin Pathol 2010; 134:568-72.
51. Parekh BS, Kalou MB, Alemnji G, Ou CY, Gershy-Damet GM, Nkengasong JN. Scaling up HIV rapid testing in developing countries: comprehensive approach for implementing quality assurance. Am J Clin Pathol 2010; 134:573-84.
52. World Health Organization. Global tuberculosis control: WHO report 2010. Geneva, Switzerland:WHO, 2010. whqlibdoc.who.int/publications/2010/ 9789241564069-eng.pdf. Accessed 28 October 2011.
53. World Health Organization. Priorities in operational research to improve tuberculosis care and control. Geneva, Switzerland: WHO, 2011. http://www.stoptb.org/assets/documents/resources/publications/technical/ StopTB%20Guide.pdf. Accessed 28 October 2011.
54. World Health Organization. New technologies for TB control: a framework for their adoption, introduction and implementation. Geneva, Switzerland: WHO, 2007. whqlibdoc.who.int/publications/2007/9789241595520-eng.pdf. Accessed 28 October 2011.
55. Parsons LM, Somoskovi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011; 24:314-50.
56. Vynnycky E, White R. An introduction to infectious disease modelling. Oxford: Oxford University Press, 2010.
57. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005.
58. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
59. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570-85.
60. Walensky RP, Wood R, Fofana MO, et al. The clinical impact and costeffectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 2010; 56:26-35.
61. Dowdy DW, O'Brien MA, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2008; 12:1021-9.
62. Loubiere S, Moatti JP. Economic evaluation of point-of-care diagnostic technologies for infectious diseases. Clin Microbiol Infect 2010; 16: 1070-6.
63. Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 2011; 8:e1001063.
64. Delaney KP, Branson BM, Uniyal A, et al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 2006; 20:1655-60.
65. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1-196.
66. Phanuphak N, Pattanachaiwit S, Pankam T, et al. Active voluntary counseling and testing with integrated CD4 count service can enhance early HIV testing and early CD4 count measurement: experiences from the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. J Acquir Immune Defic Syndr 2010; 56:244-52.
67. Lin HH, Langley I, Mwenda R, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2011; 15:996-1004.